Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
Rhea-AI Summary
Armata Pharmaceuticals (NYSE American: ARMP) appointed Daniel B. Gilmer, Ph.D. to its Board of Directors, effective April 24, 2026. Dr. Gilmer currently serves at Pfizer and has experience leading commercial launches, quality oversight for 50+ U.S. brands, and advancing anti-infective programs including work on PAXLOVID and phage-related research.
The appointment adds commercial and access expertise intended to support Armata's late clinical-stage, bacteriophage therapeutic pipeline against antibiotic-resistant infections.
Positive
- Appointed Daniel B. Gilmer to Board, effective April 24, 2026
- Dr. Gilmer led the U.S. launch of PAXLOVID following FDA New Drug Approval
- Leads quality and promotional review across 50+ U.S. brands at Pfizer
- Co-inventor on Exebacase patent and author of phage lysin publications
Negative
- None.
News Market Reaction – ARMP
In the Apr 27 session, ARMP declined 14.86%, reflecting a significant negative market reaction. Argus tracked a trough of -25.2% from its starting point during tracking. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
"I am pleased to welcome Daniel to our Board and look forward to leveraging his many years of experience spanning scientific discovery, commercial strategy, and patient access," stated Robin C. Kramer, Chair of Armata's Board of Directors. "Daniel has discovered and helped advance first-in-class anti-infective candidates and has played pivotal roles in the launch and commercialization of breakthrough therapies and diagnostics, including leading the
"I am very excited to join Armata's Board and work alongside my fellow Directors and the leadership team to help the Company achieve its clinical and commercial goals," stated Dr. Gilmer. "Armata is developing precisely targeted bacteriophage therapeutics that have the potential to address the growing global crisis of antibiotic resistance. I look forward to contributing my experience in launching innovative anti-infectives and access-oriented initiatives to support this mission."
Daniel B. Gilmer, Ph.D. is an accomplished healthcare executive. At Pfizer, he leads an organization responsible for quality and promotional review across 50+
Dr. Gilmer is an equal co-inventor on the patent for Exebacase (also termed "CF-301" or "PlySs2"), a first-in-class Streptococcus bacteriophage lysin. Exebacase received Fast Track and Breakthrough Therapy designations from the FDA before advancing to Phase 3 clinical trials. Dr. Gilmer has authored multiple peer-reviewed publications on phage lysins and antimicrobial resistance. Prior to joining Pfizer, Dr. Gilmer worked at McKinsey & Co. focusing on commercial growth strategies, market access, and lean manufacturing in
He has a Ph.D. in Microbiology from Rockefeller University (RU) and a B.S. from Howard University. As an RU alum, he serves on both the RU Board of Trustees Educational Affairs Committee and the RU Ford Center Incubator selection committee. He is a member of the New York Academy of Sciences and a term member at the Council on Foreign Relations.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.
Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-appointment-of-biopharmaceutical-commercial-executive-daniel-b-gilmer-phd-to-its-board-of-directors-302753455.html
SOURCE Armata Pharmaceuticals, Inc.